TD Cowen Maintains Buy on UroGen Pharma, Raises Price Target to $60

Benzinga · 1d ago
TD Cowen analyst Tara Bancroft maintains UroGen Pharma (NASDAQ:URGN) with a Buy and raises the price target from $50 to $60.